M/S Cipla Ltd. v. Commnr. of Central Excise, Bangalore
In short. This case involves a statutory appeal filed by M/s. Cipla Ltd against the Commissioner of Central Excise, Bangalore, concerning the classification and excisability of Benzyl Methyl Salicylate (BMS). The core issue was whether BMS was a marketable product liable to excise duty under the Central Excise Act, 1944. The Supreme Court upheld the Tribunal's decision that BMS was indeed marketable and thus subject to excise duty. The court's reasoning centered on the interpretation of marketability and the evidence presented regarding the sale and distribution of BMS.
Facts
M/s. Cipla Ltd, engaged in manufacturing medicines and organic chemicals, declared BMS as a non-excisable item in their classification lists submitted in 1986 and 1987. The Revenue issued show cause notices in 1987, asserting that BMS was liable for excise duty. Cipla contended that BMS was neither sold nor purchased by any party, thus not excisable. The Assistant Collector initially ruled that BMS was excisable, leading to a series of legal challenges, including a writ petition in the High Court, which quashed the initial order and remanded the case for further examination. After further proceedings, the Assistant Collector reaffirmed the excisability of BMS, which was subsequently upheld by the Tribunal.
Arguments
Petitioner Arguments
Cipla argued that BMS was not an excisable commodity as it was not sold or purchased in the market. They contended that the Revenue failed to provide adequate grounds for the proposed duty and that the inquiries into the marketability of BMS yielded no substantial evidence. The court addressed these arguments by emphasizing the importance of marketability in determining excisability and noted that Cipla's evidence did not sufficiently demonstrate that BMS was not marketable.
Respondent Arguments
The Commissioner of Central Excise argued that BMS was marketable and thus subject to excise duty. They pointed to the classification under the Tariff Act and the lack of evidence from Cipla to support their claim of non-marketing. The court found the respondent's arguments compelling, particularly in light of the legal standards regarding marketability and the burden of proof resting on the petitioner to demonstrate non-excisability.
Precedents considered
The court cited the case of Bhor Industries Ltd. v. C.C.E., which established that the determination of marketability is crucial in excise duty cases. This precedent was applied to assess whether BMS could be considered marketable based on the evidence presented.
Legal principles
The court considered the principle of marketability as a key factor in determining excisability under the Central Excise Act. The burden of proof lies with the manufacturer to demonstrate that the product is not marketable. The court also examined the classification of goods under the Central Excise Tariff Act, which influences the applicability of excise duty.
Decision and reasoning
Rationale
The court's reasoning highlighted the inadequacy of Cipla's evidence to prove that BMS was not marketable. The court noted that the absence of sales or purchases alone does not negate marketability, and the lack of evidence from the Revenue was not sufficient to overturn the Tribunal's findings. The court emphasized the need for a comprehensive assessment of marketability based on available evidence.
Outcome
The Supreme Court dismissed the appeal, affirming the Tribunal's decision that BMS was marketable and subject to excise duty. The court did not provide specific instructions for the appeal process, as the decision was final.
Conclusion
This judgment reinforces the legal principle that marketability is a critical factor in determining excisability under the Central Excise Act. It underscores the importance of evidence in establishing claims of non-excisability and clarifies the burden of proof on manufacturers. The case serves as a significant reference for future disputes regarding the classification and excisability of products in the pharmaceutical and chemical industries.
Read the full judgment on the Supreme Court website (PDF)
Find the judgments that followed or distinguished it, with the paragraph relied on in each. Two answers free on WhatsApp, no signup.